Table 2.
Dosage and application intervals
| n = (%) | Application intervals (months) | |
|---|---|---|
| All patients | ||
| Number of RTX infusions | ||
| 1st course | 153 | |
| 2nd course | 130 | 9.7 ± 4.5 |
| 3rd course | 93 | 9.8 ± 5.2 |
| During whole follow-up | 521 | 9.7 ± 4.72 |
| Single RTX dosage (mg) | ||
| 250 | 98 (18.8) | 6.4 ± 2.1 |
| 500 | 207 (39.7) | 9.1 ± 4.4 |
| 1000 | 153 (29.4) | 14.7 ± 6.7 |
| > 1000 | 63 (12.1) | 11.4 ± 2.0 |
| RRMS | ||
| Number of RTX infusions | ||
| 1st course | 72 | |
| 2nd course | 59 | |
| 3rd course | 47 | |
| During whole follow-up | 269 | |
| Single RTX dosage (mg) | ||
| 250 | 60 (22.3) | 6.4 ± 2.6 |
| 500 | 110 (40.9) | 8.7 ± 3.7 |
| 1000 | 62 (23.0) | 14.3 ± 6.5 |
| > 1000 | 37 (13.8) | 11 ± 3.1 |
| SPMS | ||
| Number of RTX infusions | ||
| 1st course | 60 | |
| 2nd course | 54 | |
| 3rd course | 29 | |
| During whole follow-up | 187 | |
| Single RTX dosage (mg) | ||
| 250 | 38 (20.3) | 7.2 ± 2.6 |
| 500 | 97 (51.9) | 9.3 ± 3.4 |
| 1000 | 43 (23.0) | 13 ± 7.4 |
| > 1000 | 9 (4.8) | 11 ± 9.3 |
| NMO/NMOSD | ||
| Number of RTX infusions | ||
| 1st course | 21 | |
| 2nd course | 17 | |
| 3rd course | 17 | |
| During whole follow-up | 65 | |
| Single RTX dosage (mg) | ||
| 1000 | 48 (73.8) | 7.2 ± 3.5 |
| > 1000 | 17 (26.2) | 9.5 ± 3.7 |
Data are expressed as mean ± SD where appropriate
n number of patients, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disease, RRMS relapsing–remitting MS, RTX rituximab, SPMS secondary progressive MS